Business Context and Reporting Period
This Form 8-K is a current report filed by Akers Biosciences, Inc. (the "Company") on April 17, 2020. The report details corporate events occurring between April 7, 2020, and April 16, 2020, specifically regarding the exercise of warrants and subsequent conversion of preferred stock.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data relates to capital structure changes:
- Warrant Exercise Price: $4.00 per share of Series C Preferred Stock.
- Shares Issued: 1,043,500 shares of Series C Preferred Stock were issued upon warrant exercise and immediately converted into 1,043,500 shares of common stock.
- Outstanding Common Stock (as of April 17, 2020): 4,755,407 shares.
- Remaining Outstanding Warrants: Warrants to purchase 946,500 shares of Series C Preferred Stock (convertible into 946,500 shares of common stock).
Material Changes Versus Prior Period
The material change reported is the increase in outstanding common stock due to the exercise of warrants. Between April 7 and April 16, 2020, the Company issued an additional 1,043,500 shares of common stock following the conversion of Series C Preferred Stock. The filing does not provide comparative data for prior periods regarding stock counts or financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the disclosure of the capital transaction. The document is a factual report of the warrant exercises and resulting share counts. No unusual items or contingencies are disclosed in this specific report.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (4,755,407) and the dilution impact of the 1,043,500 newly issued shares.
- Confirm the remaining warrant overhang of 946,500 shares and the associated conversion terms.
- Note that this filing does not contain financial results; investors should refer to the most recent 10-Q or 10-K for revenue and cash flow data.
- Confirm the exercise price of $4.00 per share for the Series C Preferred Stock warrants.